The DOI matches its Crossref record; 1,264 of the 1,264 references it cites were found in a registry or an index.
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Open accessAbstract
Tumor biomarkers, the substances which are produced by tumors or the body’s responses to tumors during tumorigenesis and progression, have been demonstrated to possess critical and encouraging value in screening and early diagnosis, prognosis prediction, recurrence detection, and therapeutic efficacy monitoring of cancers. Over the past decades, continuous progress has been made in exploring and discovering novel, sensitive, specific, and accurate tumor biomarkers, which has significantly promoted personalized medicine and improved the outcomes of cancer patients, especially advances in molecular biology technologies developed for the detection of tumor biomarkers. Herein, we summarize the discovery and development of tumor biomarkers, including the history of tumor biomarkers, the conventional and innovative technologies used for biomarker discovery and detection, the classification of tumor biomarkers based on tissue origins, and the application of tumor biomarkers in clinical cancer management. In particular, we highlight the recent advancements in biomarker-based anticancer-targeted therapies which are emerging as breakthroughs and promising cancer therapeutic strategies. We also discuss limitations and challenges that need to be addressed and provide insights and perspectives to turn challenges into opportunities in this field. Collectively, the discovery and application of multiple tumor biomarkers emphasized in this review may provide guidance on improved precision medicine, broaden horizons in future research directions, and expedite the clinical classification of cancer patients according to their molecular biomarkers rather than organs of origin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Items 401–600 of 1,264
Takahashi, N., Duprez, L., Grootjans, S., Cauwels, A., Nerinckx, W., DuHadaway, J. B., Goossens, V, Roelandt, R., Van Hauwermeiren, F., Libert, C., et al. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.176 · Cited by 465
CDK4 and CDK6 kinases: From basic science to cancer therapy
Fassl, A., Geng, Y., & Sicinski, P. (2022) · Science · doi:10.1126/science.abc1495 · Cited by 464
BET Proteins as Targets for Anticancer Treatment
Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463
Differentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
Stein, E. M., Garcia-Manero, G., Rizzieri, D. A., Tibes, R., Berdeja, J. G., Savona, M. R., Jongen-Lavrenic, M., Altman, J. K., Thomson, B., Blakemore, S. J., et al. (2018) · Blood · doi:10.1182/blood-2017-12-818948 · Cited by 461
Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?
Duffy, M. J. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.059832 · Cited by 460
Histopathology Procedures: From Tissue Sampling to Histopathological Evaluation
Slaoui, M., & Fiette, L. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-849-2_4 · Cited by 455
Systems Biology of Cancer Metastasis
Suhail, Y., Cain, M. P., Vanaja, K., Kurywchak, P. A., Levchenko, A., Kalluri, R., & Kshitiz (2019) · Cell Systems · doi:10.1016/j.cels.2019.07.003 · Cited by 452
E-cadherin—catenin cell—cell adhesion complex and human cancer
Wijnhoven, B. P. L., Dinjens, W. N. M., & Pignatelli, M. (2000) · Journal of British Surgery · doi:10.1046/j.1365-2168.2000.01513.x · Cited by 451
Targeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACs
Bond, M. J., Chu, L., Nalawansha, D. A., Li, K., & Crews, C. M. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00411 · Cited by 450
miR-200–containing extracellular vesicles promote breast cancer cell metastasis
Le, M. T. N., Hamar, P., Guo, C., Basar, E., Perdigão-Henriques, R., Balaj, L., & Lieberman, J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75695 · Cited by 449
Histone deacetylase inhibitors in cancer therapy
Johnstone, R. W., & Licht, J. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00165-x · Cited by 449
Janku, F., Wheler, J. J., Westin, S. N., Moulder, S. L., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido-Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 447
Smith, D. C., Smith, M. R., Sweeney, C., Elfiky, A. A., Logothetis, C., Corn, P. G., Vogelzang, N. J., Small, E. J., Harzstark, A. L., Gordon, M. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0494 · Cited by 446
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter
Luo, G., Jin, K., Deng, S., Cheng, H., Fan, Z., Gong, Y., Qian, Y., Huang, Q., Ni, Q., Liu, C., et al. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188409 · Cited by 446
Hofmann, M. H., Gmachl, M., Ramharter, J., Savarese, F., Gerlach, D., Marszalek, J. R., Sanderson, M. P., Kessler, D., Trapani, F., Arnhof, H., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0142 · Cited by 444
Mayer, B., Johnson, J. P., Leitl, F., Jauch, K. W., Heiss, M. M., Schildberg, F. W., Birchmeier, W., & Funke, I. (1993) · PubMed · Cited by 440
Andronesi, O. C., Kim, G. S., Gerstner, E., Batchelor, T., Tzika, A. A., Fantin, V. R., Vander Heiden, M. G., & Sorensen, A. G. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002693 · Cited by 438
Comprehensive analysis of HE4 expression in normal and malignant human tissues
Galgano, M. T., Hampton, G. M., & Frierson, H. F. (2006) · Modern Pathology · doi:10.1038/modpathol.3800612 · Cited by 437
RB1: a prototype tumor suppressor and an enigma
Dyson, N. J. (2016) · Genes & Development · doi:10.1101/gad.282145.116 · Cited by 435
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Platten, M., Bunse, L., Wick, A., Bunse, T., Le Cornet, L., Harting, I., Sahm, F., Sanghvi, K., Tan, C. L., Poschke, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03363-z · Cited by 432
Nanopore-Based Fourth-Generation DNA Sequencing Technology
Feng, Y., Zhang, Y., Ying, C., Wang, D., & Du, C. (2015) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2015.01.009 · Cited by 431
Self-citationInducing and exploiting vulnerabilities for the treatment of liver cancer
Wang, C., Vegna, S., Jin, H., Benedict, B., Lieftink, C., Ramirez, C., de Oliveira, R. L., Morris, B., Gadiot, J., Wang, W., et al. (2019) · Nature · doi:10.1038/s41586-019-1607-3 · Cited by 427
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 426
Sullivan, R. J., Infante, J. R., Janku, F., Wong, D. J. L., Sosman, J. A., Keedy, V., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1119 · Cited by 426
McAfee, Q., Zhang, Z., Samanta, A., Levi, S. M., Ma, X.-H., Piao, S., Lynch, J. P., Uehara, T., Sepulveda, A. R., Davis, L. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118193109 · Cited by 422
Therapeutic strategies to target RAS-mutant cancers
Ryan, M. B., & Corcoran, R. B. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0105-0 · Cited by 420
Gupta, S., Bent, S., & Kohlwes, J. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-1-200307010-00012 · Cited by 420
Chen, W.-X., Liu, X.-M., Lv, M.-M., Chen, L., Zhao, J.-H., Zhong, S.-L., Ji, M.-H., Hu, Q., Luo, Z., Wu, J.-Z., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095240 · Cited by 420
Santos, E., Martin-Zanca, D., Reddy, E. P., Pierotti, M. A., Della Porta, G., & Barbacid, M. (1984) · Science · doi:10.1126/science.6695174 · Cited by 418
mTOR signaling and drug development in cancer
Dancey, J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.21 · Cited by 417
Role of the NLRP3 inflammasome in cancer
Moossavi, M., Parsamanesh, N., Bahrami, A., Atkin, S. L., & Sahebkar, A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0900-3 · Cited by 417
Dietary modifications for enhanced cancer therapy
Kanarek, N., Petrova, B., & Sabatini, D. M. (2020) · Nature · doi:10.1038/s41586-020-2124-0 · Cited by 411
The interaction of p62 with RIP links the atypical PKCs to NF-kappa B activation
Sanz, L. (1999) · The EMBO Journal · doi:10.1093/emboj/18.11.3044 · Cited by 410
Exosomal miRNAs as cancer biomarkers and therapeutic targets
Thind, A., & Wilson, C. (2016) · Journal of Extracellular Vesicles · doi:10.3402/jev.v5.31292 · Cited by 404
She, Q.-B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D. B., & Rosen, N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.023 · Cited by 400
Papke, B., & Der, C. J. (2017) · Science · doi:10.1126/science.aam7622 · Cited by 399
Kirchhoff, C., Habben, I., Ivell, R., & Krull, N. (1991) · Biology of Reproduction · doi:10.1095/biolreprod45.2.350 · Cited by 395
Cadherin Adhesion and Mechanotransduction
Leckband, D. E., & de Rooij, J. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013212 · Cited by 394
p62 in Cancer: Signaling Adaptor Beyond Autophagy
Moscat, J., Karin, M., & Diaz-Meco, M. T. (2016) · Cell · doi:10.1016/j.cell.2016.09.030 · Cited by 391
Hillig, R. C., Sautier, B., Schroeder, J., Moosmayer, D., Hilpmann, A., Stegmann, C. M., Werbeck, N. D., Briem, H., Boemer, U., Weiske, J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1812963116 · Cited by 388
Marrero, J. A., Su, G. L., Wei, W., Emick, D., Conjeevaram, H. S., Fontana, R. J., & Lok, A. S. (2003) · Hepatology · doi:10.1053/jhep.2003.50195 · Cited by 387
Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., & Zunino, F. (1996) · PubMed · Cited by 384
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer
Zhang, M., Cheng, S., Jin, Y., Zhao, Y., & Wang, Y. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188503 · Cited by 384
Self-citationRAF inhibitors that evade paradoxical MAPK pathway activation
Zhang, C., Spevak, W., Zhang, Y., Burton, E. A., Ma, Y., Habets, G., Zhang, J., Lin, J., Ewing, T., Matusow, B., et al. (2015) · Nature · doi:10.1038/nature14982 · Cited by 382
Self-citationThe telomerase reverse transcriptase regulates chromatin state and DNA damage responses
Masutomi, K., Possemato, R., Wong, J. M. Y., Currier, J. L., Tothova, Z., Manola, J. B., Ganesan, S., Lansdorp, P. M., Collins, K., & Hahn, W. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503095102 · Cited by 382
The implications of IDH mutations for cancer development and therapy
Pirozzi, C. J., & Yan, H. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00521-0 · Cited by 382
Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA
Ye, Q., Ling, S., Zheng, S., & Xu, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1043-x · Cited by 379
MDM2 inhibition: an important step forward in cancer therapy
Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., Wei, A., Higgins, B., Ott, M., Mascarenhas, J., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376
Diagnostic and prognostic value of CEA, CA19–9, AFP and CA125 for early gastric cancer
Feng, F., Tian, Y., Xu, G., Liu, Z., Liu, S., Zheng, G., Guo, M., Lian, X., Fan, D., & Zhang, H. (2017) · BMC Cancer · doi:10.1186/s12885-017-3738-y · Cited by 373
Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase
Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370
Application and interpretation of current autophagy inhibitors and activators
Yang, Y.-P., Hu, L.-F., Zheng, H.-F., Mao, C.-J., Hu, W.-D., Xiong, K.-P., Wang, F., & Liu, C.-F. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.5 · Cited by 370
ATR/CHK1 inhibitors and cancer therapy
Qiu, Z., Oleinick, N. L., & Zhang, J. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.09.043 · Cited by 370
Wu, Y., Deng, W., & Klinke II, D. J. (2015) · The Analyst · doi:10.1039/c5an00688k · Cited by 369
Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708148104 · Cited by 367
BET inhibitors: a novel epigenetic approach
Doroshow, D. B., Eder, J. P., & LoRusso, P. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx157 · Cited by 367
Tumour necrosis factor-α as a tumour promoter
Szlosarek, P., Charles, K. A., & Balkwill, F. R. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.012 · Cited by 366
Petherick, K. J., Conway, O. J. L., Mpamhanga, C., Osborne, S. A., Kamal, A., Saxty, B., & Ganley, I. G. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.c114.627778 · Cited by 366
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Dienstmann, R., Rodon, J., Prat, A., Perez-Garcia, J., Adamo, B., Felip, E., Cortes, J., Iafrate, A. J., Nuciforo, P., & Tabernero, J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt419 · Cited by 365
Shikonin circumvents cancer drug resistance by induction of a necroptotic death
Han, W., Li, L., Qiu, S., Lu, Q., Pan, Q., Gu, Y., Luo, J., & Hu, X. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0511 · Cited by 364
Rong, S., Segal, S., Anver, M., Resau, J. H., & Vande Woude, G. F. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4731 · Cited by 363
Cause of Cushing's Syndrome in Patients with Tumors Arising from “Nonendocrine” Tissue
MEADOR, C. K., LIDDLE, G. W., ISLAND, D. P., NICHOLSON, W. E., LUCAS, C. P., NUCKTON, J. G., & LUETSCHER, J. A. (1962) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-22-7-693 · Cited by 363
Tracking cancer progression: from circulating tumor cells to metastasis
Castro-Giner, F., & Aceto, N. (2020) · Genome Medicine · doi:10.1186/s13073-020-00728-3 · Cited by 363
Rapamycin inhibits the secretory phenotype of senescent cells by a Nrf2-independent mechanism
Wang, R., Yu, Z., Sunchu, B., Shoaf, J., Dang, I., Zhao, S., Caples, K., Bradley, L., Beaver, L. M., Ho, E., et al. (2017) · Aging Cell · doi:10.1111/acel.12587 · Cited by 360
Johnson, P. J. (2001) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70158-6 · Cited by 359
TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation
Jouan-Lanhouet, S., Arshad, M. I., Piquet-Pellorce, C., Martin-Chouly, C., Le Moigne-Muller, G., Van Herreweghe, F., Takahashi, N., Sergent, O., Lagadic-Gossmann, D., Vandenabeele, P., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2012.90 · Cited by 357
Mrozik, K. M., Blaschuk, O. W., Cheong, C. M., Zannettino, A. C. W., & Vandyke, K. (2018) · BMC Cancer · doi:10.1186/s12885-018-4845-0 · Cited by 356
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
Tumour necrosis factor α: a potential target for the therapy of solid tumours
Szlosarek, P. W., & Balkwill, F. R. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01196-3 · Cited by 355
Fasting-mimicking diet and hormone therapy induce breast cancer regression
Caffa, I., Spagnolo, V., Vernieri, C., Valdemarin, F., Becherini, P., Wei, M., Brandhorst, S., Zucal, C., Driehuis, E., Ferrando, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2502-7 · Cited by 355
The E-cadherin–catenin complex in tumour metastasis
Beavon, I. R. G. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00158-1 · Cited by 353
The MYST family of histone acetyltransferases and their intimate links to cancer
Avvakumov, N., & Côté, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210608 · Cited by 353
Cell-Cycle Therapeutics Come of Age
Ingham, M., & Schwartz, G. K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.0032 · Cited by 353
Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352
Modest, D. P., Ricard, I., Heinemann, V., Hegewisch-Becker, S., Schmiegel, W., Porschen, R., Stintzing, S., Graeven, U., Arnold, D., von Weikersthal, L. F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw261 · Cited by 351
CA 19-9: Biochemical and Clinical Aspects
Scarà, S., Bottoni, P., & Scatena, R. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-017-7215-0_15 · Cited by 351
Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Boquimpani, C., Pasquini, R., Clark, R. E., et al. (2021) · Leukemia · doi:10.1038/s41375-020-01111-2 · Cited by 351
Hu, Y., Yan, C., Mu, L., Huang, K., Li, X., Tao, D., Wu, Y., & Qin, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125625 · Cited by 348
Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Prasanna, P. G., Citrin, D. E., Hildesheim, J., Ahmed, M. M., Venkatachalam, S., Riscuta, G., Xi, D., Zheng, G., Deursen, J. V., Goronzy, J., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab064 · Cited by 348
Resistance to Anti-Angiogenic Therapy in Cancer—Alterations to Anti-VEGF Pathway
Itatani, Y., Kawada, K., Yamamoto, T., & Sakai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041232 · Cited by 346
Drug-sensitive FGFR2 mutations in endometrial carcinoma
Dutt, A., Salvesen, H. B., Chen, T.-H., Ramos, A. H., Onofrio, R. C., Hatton, C., Nicoletti, R., Winckler, W., Grewal, R., Hanna, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803379105 · Cited by 345
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 345
Greenberg, R. A., Allsopp, R. C., Chin, L., Morin, G. B., & DePinho, R. A. (1998) · Oncogene · doi:10.1038/sj.onc.1201933 · Cited by 338
Hoy, S. M. (2020) · Drugs · doi:10.1007/s40265-020-01288-x · Cited by 338
Binenbaum, Y., Fridman, E., Yaari, Z., Milman, N., Schroeder, A., Ben David, G., Shlomi, T., & Gil, Z. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0124 · Cited by 337
Biological Role and Therapeutic Potential of IDH Mutations in Cancer
Waitkus, M. S., Diplas, B. H., & Yan, H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.011 · Cited by 335
Yokoi, A., Yoshioka, Y., Yamamoto, Y., Ishikawa, M., Ikeda, S.-I., Kato, T., Kiyono, T., Takeshita, F., Kajiyama, H., Kikkawa, F., et al. (2017) · Nature Communications · doi:10.1038/ncomms14470 · Cited by 334
Cancer therapy in the necroptosis era
Su, Z., Yang, Z., Xie, L., DeWitt, J. P., & Chen, Y. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2016.8 · Cited by 333
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., De Stefani, A., Valente, G., Giordano, S., Cortesina, G., & Comoglio, P. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203455 · Cited by 332
Factors involved in cancer metastasis: a better understanding to “seed and soil” hypothesis
Liu, Q., Zhang, H., Jiang, X., Qian, C., Liu, Z., & Luo, D. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0742-4 · Cited by 332
Recent advances in biosensor for detection of lung cancer biomarkers
Yang, G., Xiao, Z., Tang, C., Deng, Y., Huang, H., & He, Z. (2019) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.111416 · Cited by 330
A novel germ line juxtamembrane Met mutation in human gastric cancer
Lee, J.-H., Han, S.-U., Cho, H., Jennings, B., Gerrard, B., Dean, M., Schmidt, L., Zbar, B., & Vande Woude, G. F. (2000) · Oncogene · doi:10.1038/sj.onc.1203874 · Cited by 329
Wang, S., Sun, W., Zhao, Y., McEachern, D., Meaux, I., Barrière, C., Stuckey, J. A., Meagher, J. L., Bai, L., Liu, L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0799 · Cited by 328
Self-citationDNA Methylation, Its Mediators and Genome Integrity
Meng, H., Cao, Y., Qin, J., Song, X., Zhang, Q., Shi, Y., & Cao, L. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.11218 · Cited by 327
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0634 · Cited by 325
Chandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., Ismail, S. A., Hedberg, C., Hanzal-Bayer, M., Venkitaraman, A. R., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2394 · Cited by 325
Petrelli, F., Cabiddu, M., Coinu, A., Borgonovo, K., Ghilardi, M., Lonati, V., & Barni, S. (2015) · Acta Oncologica · doi:10.3109/0284186x.2015.1043026 · Cited by 323
Chang, E. H., Gonda, M. A., Ellis, R. W., Scolnick, E. M., & Lowy, D. R. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.16.4848 · Cited by 322
Targeting mitochondrial metabolism for precision medicine in cancer
Sainero-Alcolado, L., Liaño-Pons, J., Ruiz-Pérez, M. V., & Arsenian-Henriksson, M. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-01022-y · Cited by 322
Fakih, M. G., Kopetz, S., Kuboki, Y., Kim, T. W., Munster, P. N., Krauss, J. C., Falchook, G. S., Han, S.-W., Heinemann, V., Muro, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00605-7 · Cited by 320
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
Bax activation and mitochondrial insertion during apoptosis
Lalier, L., Cartron, P.-F., Juin, P., Nedelkina, S., Manon, S., Bechinger, B., & Vallette, F. M. (2007) · Apoptosis · doi:10.1007/s10495-007-0749-1 · Cited by 320
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma
Johnson, P., Zhou, Q., Dao, D. Y., & Lo, Y. M. D. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00620-y · Cited by 320
Song, P., Wu, L. R., Yan, Y. H., Zhang, J. X., Chu, T., Kwong, L. N., Patel, A. A., & Zhang, D. Y. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00837-3 · Cited by 319
A TRP Channel in the Lysosome Regulates Large Particle Phagocytosis via Focal Exocytosis
Samie, M., Wang, X., Zhang, X., Goschka, A., Li, X., Cheng, X., Gregg, E., Azar, M., Zhuo, Y., Garrity, A. G., et al. (2013) · Developmental Cell · doi:10.1016/j.devcel.2013.08.003 · Cited by 317
Aucamp, J., Bronkhorst, A. J., Badenhorst, C. P. S., & Pretorius, P. J. (2018) · Biological Reviews · doi:10.1111/brv.12413 · Cited by 317
Contribution of Angiogenesis to Inflammation and Cancer
Aguilar-Cazares, D., Chavez-Dominguez, R., Carlos-Reyes, A., Lopez-Camarillo, C., Hernadez de la Cruz, O. N., & Lopez-Gonzalez, J. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01399 · Cited by 317
Tumor endothelial cells accelerate tumor metastasis
Maishi, N., & Hida, K. (2017) · Cancer Science · doi:10.1111/cas.13336 · Cited by 316
The metabolic landscape of RAS-driven cancers from biology to therapy
Mukhopadhyay, S., Vander Heiden, M. G., & McCormick, F. (2021) · Nature Cancer · doi:10.1038/s43018-021-00184-x · Cited by 315
Inside HDACs with more selective HDAC inhibitors
Roche, J., & Bertrand, P. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.047 · Cited by 312
Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
André, F., Bachelot, T., Campone, M., Dalenc, F., Perez-Garcia, J. M., Hurvitz, S. A., Turner, N., Rugo, H., Smith, J. W., Deudon, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0190 · Cited by 311
Self-citationTargeting epigenetic regulators to overcome drug resistance in cancers
Wang, N., Ma, T., & Yu, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01341-7 · Cited by 311
Novel anticancer therapeutics targeting telomerase
Ruden, M., & Puri, N. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.06.007 · Cited by 310
Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
Higgins, M. J., Jelovac, D., Barnathan, E., Blair, B., Slater, S., Powers, P., Zorzi, J., Jeter, S. C., Oliver, G. R., Fetting, J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2696 · Cited by 309
Durant, S. T., Zheng, L., Wang, Y., Chen, K., Zhang, L., Zhang, T., Yang, Z., Riches, L., Trinidad, A. G., Fok, J. H. L., et al. (2018) · Science Advances · doi:10.1126/sciadv.aat1719 · Cited by 309
Lim, C.-Y., Davis, O. B., Shin, H. R., Zhang, J., Berdan, C. A., Jiang, X., Counihan, J. L., Ory, D. S., Nomura, D. K., & Zoncu, R. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0391-5 · Cited by 308
Immunoassays with time-resolved fluorescence spectroscopy: Principles and applications
Diamandis, E. P. (1988) · Clinical Biochemistry · doi:10.1016/0009-9120(88)90001-x · Cited by 307
Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
Goyal, L., Muzumdar, M. D., & Zhu, A. X. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2791 · Cited by 307
Lazova, R., Camp, R. L., Klump, V., Siddiqui, S. F., Amaravadi, R. K., & Pawelek, J. M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1282 · Cited by 305
The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects
Jurisic, V., Radenkovic, S., & Konjevic, G. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-017-7215-0_8 · Cited by 304
Fluoroimmunoassays and immunofluorometric assays.
Hemmilä, I. (1985) · Clinical Chemistry · doi:10.1093/clinchem/31.3.359 · Cited by 303
Liang, X., Yu, J., Brown, K., & Levine, B. (2001) · PubMed · Cited by 303
Ni, X. G., Bai, X. F., Mao, Y. L., Shao, Y. F., Wu, J. X., Shan, Y., Wang, C. F., Wang, J., Tian, Y. T., Liu, Q., et al. (2005) · European Journal of Surgical Oncology (EJSO) · doi:10.1016/j.ejso.2004.09.007 · Cited by 303
Padanad, M. S., Konstantinidou, G., Venkateswaran, N., Melegari, M., Rindhe, S., Mitsche, M., Yang, C., Batten, K., Huffman, K. E., Liu, J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.009 · Cited by 301
Genomic Analysis in the Age of Human Genome Sequencing
Lappalainen, T., Scott, A. J., Brandt, M., & Hall, I. M. (2019) · Cell · doi:10.1016/j.cell.2019.02.032 · Cited by 301
Janku, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M., Fu, S., Piha-Paul, S. A., Lee, J. J., Luthra, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1726 · Cited by 300
Gilligan, T. D., Seidenfeld, J., Basch, E. M., Einhorn, L. H., Fancher, T., Smith, D. C., Stephenson, A. J., Vaughn, D. J., Cosby, R., & Hayes, D. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4481 · Cited by 297
EMT transcription factors in cancer development re-evaluated: Beyond EMT and MET
Goossens, S., Vandamme, N., Van Vlierberghe, P., & Berx, G. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.06.006 · Cited by 295
Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876
Siebeneicher, H., Cleve, A., Rehwinkel, H., Neuhaus, R., Heisler, I., Müller, T., Bauser, M., & Buchmann, B. (2016) · ChemMedChem · doi:10.1002/cmdc.201600276 · Cited by 294
Peng, S.-B., Henry, J. R., Kaufman, M. D., Lu, W.-P., Smith, B. D., Vogeti, S., Rutkoski, T. J., Wise, S., Chun, L., Zhang, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.002 · Cited by 294
Self-citationLin, J., Sampath, D., Nannini, M. A., Lee, B. B., Degtyarev, M., Oeh, J., Savage, H., Guan, Z., Hong, R., Kassees, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3072 · Cited by 294
Beclin1: A role in membrane dynamics and beyond
Wirawan, E., Lippens, S., Vanden Berghe, T., Romagnoli, A., Fimia, G. M., Piacentini, M., & Vandenabeele, P. (2012) · Autophagy · doi:10.4161/auto.8.1.16645 · Cited by 293
Morton, R. A., Ewing, C. M., Nagafuchi, A., Tsukita, S., & Isaacs, W. B. (1993) · PubMed · Cited by 292
Next-Generation Sequencing and Emerging Technologies
Kumar, K. R., Cowley, M. J., & Davis, R. L. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1688446 · Cited by 292
Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices
Malla, M., Loree, J. M., Kasi, P. M., & Parikh, A. R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02615 · Cited by 292
Kim, H., George, E., Ragland, R. L., Rafail, S., Zhang, R., Krepler, C., Morgan, M. A., Herlyn, M., Brown, E. J., & Simpkins, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2273 · Cited by 291
(2014) · New England Journal of Medicine · doi:10.1056/nejmc1412266 · Cited by 291
Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer
Murray, G. I., Duncan, M. E., O'Neil, P., McKay, J. A., Melvin, W. T., & Fothergill, J. E. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199807)185:3<256::aid-path115>3.0.co;2-a · Cited by 288
Shioiri, M., Shida, T., Koda, K., Oda, K., Seike, K., Nishimura, M., Takano, S., & Miyazaki, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603193 · Cited by 287
Replication Fork Reversal: Players and Guardians
Quinet, A., Lemaçon, D., & Vindigni, A. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.11.022 · Cited by 287
Hematopoietic Malignancies Demonstrate Loss-of-Function Mutations ofBAX
Meijerink, J. P. P., Mensink, E. J. B. M., Wang, K., Sedlak, T. W., Slöetjes, A. W., de Witte, T., Waksman, G., & Korsmeyer, S. J. (1998) · Blood · doi:10.1182/blood.v91.8.2991.2991_2991_2997 · Cited by 286
Cadherins and their connections: adhesion junctions have broader functions
Steinberg, M. S., & McNutt, P. M. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)00027-7 · Cited by 286
Moores, S. L., Chiu, M. L., Bushey, B. S., Chevalier, K., Luistro, L., Dorn, K., Brezski, R. J., Haytko, P., Kelly, T., Wu, S.-J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2833 · Cited by 286
Inhibition of RAS function through targeting an allosteric regulatory site
Spencer-Smith, R., Koide, A., Zhou, Y., Eguchi, R. R., Sha, F., Gajwani, P., Santana, D., Gupta, A., Jacobs, M., Herrero-Garcia, E., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2231 · Cited by 283
Self-citationThe PDGF/PDGFR pathway as a drug target
Papadopoulos, N., & Lennartsson, J. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.007 · Cited by 283
Pappalardi, M. B., Keenan, K., Cockerill, M., Kellner, W. A., Stowell, A., Sherk, C., Wong, K., Pathuri, S., Briand, J., Steidel, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00249-x · Cited by 283
Molecular Biomarkers for the Early Detection of Ovarian Cancer
Zhang, R., Siu, M. K. Y., Ngan, H. Y. S., & Chan, K. K. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231912041 · Cited by 283
Epithelial–mesenchymal transition and its transcription factors
Debnath, P., Huirem, R. S., Dutta, P., & Palchaudhuri, S. (2022) · Bioscience Reports · doi:10.1042/bsr20211754 · Cited by 281
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis
Gu, L., Chen, M., Guo, D., Zhu, H., Zhang, W., Pan, J., Zhong, X., Li, X., Qian, H., & Wang, X. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182692 · Cited by 280
Department of Pharmaceutical Analytical Chemistry, F. O. P., & Darwish, I. A. (2006) · International Journal of Biomedical Science · doi:10.59566/ijbs.2006.2217 · Cited by 278
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy
Zhao, Y., Zhang, Y.-N., Wang, K.-T., & Chen, L. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188391 · Cited by 278
Self-citationSignificance of immunohistochemistry in breast cancer
Zaha, D. C. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i3.382 · Cited by 277
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
Athuluri-Divakar, S. K., Vasquez-Del Carpio, R., Dutta, K., Baker, S. J., Cosenza, S. C., Basu, I., Gupta, Y. K., Reddy, M. V. R., Ueno, L., Hart, J. R., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.045 · Cited by 277
Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment
Mishra, D., & Banerjee, D. (2019) · Cancers · doi:10.3390/cancers11060750 · Cited by 277
En Route to Metastasis: Circulating Tumor Cell Clusters and Epithelial-to-Mesenchymal Transition
Aceto, N., Toner, M., Maheswaran, S., & Haber, D. A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.07.006 · Cited by 276
Pearson, A., Smyth, E., Babina, I. S., Herrera-Abreu, M. T., Tarazona, N., Peckitt, C., Kilgour, E., Smith, N. R., Geh, C., Rooney, C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1246 · Cited by 276
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9–mediated leukemogenesis
Nguyen, A. T., Taranova, O., He, J., & Zhang, Y. (2011) · Blood · doi:10.1182/blood-2011-02-334359 · Cited by 275
Self-citationFlavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy
Sedlacek, H., Czech, J., Naik, R., Kaur, G., Worland, P., Losiewicz, M., Parker, B., Carlson, B., Smith, A., Senderowicz, A., et al. (1996) · International Journal of Oncology · doi:10.3892/ijo.9.6.1143 · Cited by 275
Therapeutic Targeting of Autophagy
Towers, C. G., & Thorburn, A. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.10.034 · Cited by 275
Das, V., Kalita, J., & Pal, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.064 · Cited by 275
Statin use and cancer risk: a comprehensive review
Boudreau, D. M., Yu, O., & Johnson, J. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740331003662620 · Cited by 274
Multivalent Small-Molecule Pan-RAS Inhibitors
Welsch, M. E., Kaplan, A., Chambers, J. M., Stokes, M. E., Bos, P. H., Zask, A., Zhang, Y., Sanchez-Martin, M., Badgley, M. A., Huang, C. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.006 · Cited by 274
Self-citationmicroRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer
Bhagirath, D., Yang, T. L., Bucay, N., Sekhon, K., Majid, S., Shahryari, V., Dahiya, R., Tanaka, Y., & Saini, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2069 · Cited by 274
Crucial players in glycolysis: Cancer progress
Abbaszadeh, Z., Çeşmeli, S., & Biray Avcı, Ç. (2020) · Gene · doi:10.1016/j.gene.2019.144158 · Cited by 274
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
Taieb, J., Le Malicot, K., Shi, Q., Penault Lorca, F., Bouché, O., Tabernero, J., Mini, E., Goldberg, R. M., Folprecht, G., Luc Van Laethem, J., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw272 · Cited by 273
Quigley, D., Alumkal, J. J., Wyatt, A. W., Kothari, V., Foye, A., Lloyd, P., Aggarwal, R., Kim, W., Lu, E., Schwartzman, J., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0146 · Cited by 273
In vivo Inhibition of Lung Cancer by GRN163L: A Novel Human Telomerase Inhibitor
Dikmen, Z. G., Gellert, G. C., Jackson, S., Gryaznov, S., Tressler, R., Dogan, P., Wright, W. E., & Shay, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1215 · Cited by 271
Otsuka, T., Takayama, H., Sharp, R., Celli, G. B., LaRochelle, W. J., Bottaro, D. P., Ellmore, N., Vieira, W., Owens, J. W., Anver, M. R., et al. (1998) · PubMed · doi:10.5281/zenodo.894795 · Cited by 268
Biomarkers for prostate cancer: prostate-specific antigen and beyond
Duffy, M. J. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0693 · Cited by 267
Aberrant N-cadherin expression in cancer
Cao, Z.-Q., Wang, Z., & Leng, P. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109320 · Cited by 266
Necrostatin-1 and necroptosis inhibition: Pathophysiology and therapeutic implications
Cao, L., & Mu, W. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105297 · Cited by 266
Saddoughi, S. A., Gencer, S., Peterson, Y. K., Ward, K. E., Mukhopadhyay, A., Oaks, J., Bielawski, J., Szulc, Z. M., Thomas, R. J., Selvam, S. P., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201283 · Cited by 264
Natural products reveal cancer cell dependence on oxysterol-binding proteins
Burgett, A. W. G., Poulsen, T. B., Wangkanont, K., Anderson, D. R., Kikuchi, C., Shimada, K., Okubo, S., Fortner, K. C., Mimaki, Y., Kuroda, M., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.625 · Cited by 262
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
Steelman, L. S., Franklin, R. A., Abrams, S. L., Chappell, W., Kempf, C. R., Bäsecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., et al. (2011) · Leukemia · doi:10.1038/leu.2011.66 · Cited by 261
p50cdc37 Acting in Concert with Hsp90 Is Required for Raf-1 Function
Grammatikakis, N., Lin, J.-H., Grammatikakis, A., Tsichlis, P. N., & Cochran, B. H. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.3.1661 · Cited by 261
Song, Y., Fu, Y., Xie, Q., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01956 · Cited by 261
Zhou, H., Zhu, L., Song, J., Wang, G., Li, P., Li, W., Luo, P., Sun, X., Wu, J., Liu, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01556-2 · Cited by 261
Self-citationp62- and ubiquitin-dependent stress-induced autophagy of the mammalian 26S proteasome
Cohen-Kaplan, V., Livneh, I., Avni, N., Fabre, B., Ziv, T., Kwon, Y. T., & Ciechanover, A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615455113 · Cited by 260
Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M., Wilhelm, S. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0993-t · Cited by 258
Gut microbiota, inflammation and colorectal cancer
Sun, J., & Kato, I. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.03.004 · Cited by 257
Targeting telomerase for cancer therapy
Guterres, A. N., & Villanueva, J. (2020) · Oncogene · doi:10.1038/s41388-020-01405-w · Cited by 256
Cartron, P.-F., Gallenne, T., Bougras, G., Gautier, F., Manero, F., Vusio, P., Meflah, K., Vallette, F. M., & Juin, P. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.10.028 · Cited by 255
De Craene, B., Gilbert, B., Stove, C., Bruyneel, E., van Roy, F., & Berx, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3545 · Cited by 254
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
Kwitkowski, V. E., Prowell, T. M., Ibrahim, A., Farrell, A. T., Justice, R., Mitchell, S. S., Sridhara, R., & Pazdur, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0178 · Cited by 254
Interplay between the lung microbiome and lung cancer
Mao, Q., Jiang, F., Yin, R., Wang, J., Xia, W., Dong, G., Ma, W., Yang, Y., Xu, L., & Hu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.036 · Cited by 254
Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer
Akins, N. S., Nielson, T. C., & Le, H. V. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180523111351 · Cited by 253
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
Santana-Codina, N., Roeth, A. A., Zhang, Y., Yang, A., Mashadova, O., Asara, J. M., Wang, X., Bronson, R. T., Lyssiotis, C. A., Ying, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07472-8 · Cited by 252
Self-citationDirect Activation of Bax Protein for Cancer Therapy
Liu, Z., Ding, Y., Ye, N., Wild, C., Chen, H., & Zhou, J. (2016) · Medicinal Research Reviews · doi:10.1002/med.21379 · Cited by 252
Exosomal miRNAs as novel cancer biomarkers: Challenges and opportunities
Salehi, M., & Sharifi, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26481 · Cited by 251
Yang, S., Che, S. P. Y., Kurywchak, P., Tavormina, J. L., Gansmo, L. B., Correa de Sampaio, P., Tachezy, M., Bockhorn, M., Gebauer, F., Haltom, A. R., et al. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1281499 · Cited by 248
Moriwaki, K., Bertin, J., Gough, P. J., Orlowski, G. M., & Chan, F. K. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.16 · Cited by 247
The E-cadherin cell–cell adhesion complex and lung cancer invasion, metastasis, and prognosis
Bremnes, R. M., Veve, R., Hirsch, F. R., & Franklin, W. A. (2002) · Lung Cancer · doi:10.1016/s0169-5002(01)00471-8 · Cited by 246
da Rocha Dias, S., Friedlos, F., Light, Y., Springer, C., Workman, P., & Marais, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2632 · Cited by 246
Targeting autophagy-related protein kinases for potential therapeutic purpose
Xiang, H., Zhang, J., Lin, C., Zhang, L., Liu, B., & Ouyang, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.10.003 · Cited by 246
Ceci, C., Atzori, M. G., Lacal, P. M., & Graziani, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041388 · Cited by 246
Distinct mechanisms of tumor invasion and metastasis
Yilmaz, M., Christofori, G., & Lehembre, F. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.10.004 · Cited by 245
Mangerich, A., Knutson, C. G., Parry, N. M., Muthupalani, S., Ye, W., Prestwich, E., Cui, L., McFaline, J. L., Mobley, M., Ge, Z., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207829109 · Cited by 242
Lactate dehydrogenase 5: An old friend and a new hope in the war on cancer
Augoff, K., Hryniewicz-Jankowska, A., & Tabola, R. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.12.035 · Cited by 241
Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
Callahan, M. K., Rampal, R., Harding, J. J., Klimek, V. M., Chung, Y. R., Merghoub, T., Wolchok, J. D., Solit, D. B., Rosen, N., Abdel-Wahab, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208958 · Cited by 240
Yang, J., Luo, L., Zhao, C., Li, X., Wang, Z., Zeng, Z., Yang, X., Zheng, X., Jie, H., Kang, L., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73398 · Cited by 240
Self-citation
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)
Smolarz, B., Łukasiewicz, H., Samulak, D., Piekarska, E., Kołaciński, R., & Romanowicz, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052049 · Cited by 259
Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
Alum, E., Izah, S., Uti, D., Ugwu, O., Betiang, P., Basajja, M., & Ejemot-Nwadiaro, R. (2025) · Drug Design, Development and Therapy · doi:10.2147/dddt.s543211 · Cited by 63
Metadata
- Authors
- Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-05-20
- Volume
- 9
- Issue
- 1
- Pages
- 132-132
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4397293886
- Cited by
- 720
- References
- 1,264
- FWCI
- 109.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.